NCT03070574 (MesaCAPP) is a Phase 2 clinical trial of mesalamine 2400 MG (5-ASA) in Colorectal Cancer, sponsored by Christoph Gasche.

Who is sponsoring NCT03070574?

NCT03070574 is sponsored by Christoph Gasche.

What drugs are being tested in NCT03070574?

Interventions in NCT03070574: mesalamine 2400 MG (5-ASA), mesalamine 1200 MG, Placebo.

What condition does NCT03070574 study?

NCT03070574 studies Colorectal Cancer.

Is NCT03070574 still recruiting?

NCT03070574 is currently terminated. Last updated 18 April 2019.

Last reviewed 2019-04-18 · How we verify

NCT03070574: MesaCAPP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome

Terminated Phase 2 Last updated 18 April 2019

What this trial tests

Phase 2 trial testing mesalamine 2400 MG (5-ASA) in Colorectal Cancer in 8 participants. Terminated before completion.

Timeline

24 November 2017

Primary endpoint
10 April 2019

10 April 2019

Quick facts

Lead sponsor	Christoph Gasche
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	8
Start date	24 November 2017
Primary completion	10 April 2019
Estimated completion	10 April 2019
Sites	6 locations across Netherlands, Austria, Sweden, Israel, Germany, Poland

Drugs / interventions tested

mesalamine 2400 MG (5-ASA) — full drug profile →
mesalamine 1200 MG — full drug profile →
Placebo

Conditions studied

Colorectal Cancer — all drugs for Colorectal Cancer →

Sponsor

Christoph Gasche — full company profile →

Who can join

25 and older, any sex, with Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multicenter, multinational, randomized, 3-arm, double-blind, phase II clinical study with 2400mg mesalamine, 1200mg mesalamine or placebo for prevention of colorectal neoplasia in Lynch Syndrome patients for 2 years.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer.
Nowak-Sliwinska P, Scapozza L, Ruiz i Altaba A. · · 2019 · cited 107× · PMID 31034926 · DOI 10.1016/j.bbcan.2019.04.005
Molecular Mechanisms of the Antitumor Effects of Mesalazine and Its Preventive Potential in Colorectal Cancer.
Słoka J, Madej M, Strzalka-Mrozik B. · · 2023 · cited 25× · PMID 37446747 · DOI 10.3390/molecules28135081
Unraveling the Heterogeneous Mutational Signature of Spontaneously Developing Tumors in MLH1<sup>-/-</sup> Mice.
Gladbach YS, Wiegele L, Hamed M, Merkenschläger AM, et al · · 2019 · cited 8× · PMID 31581674 · DOI 10.3390/cancers11101485
Influence of Mesalazine on Ferroptosis-Related Gene Expression in In Vitro Colorectal Cancer Culture.
Słoka J, Strzałka-Mrozik B, Kubica S, Nowak I, et al · · 2025 · cited 4× · PMID 39857803 · DOI 10.3390/biomedicines13010219

Verify or expand the search:

Other recruiting trials for Colorectal Cancer

Currently open trials in the same condition.

NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03070574 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Christoph Gasche
Last refreshed: 18 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03070574.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing